Clinical Trials
19 trialsNCT00086567 2026-06-01
Predictors of Relapse of Ovarian, Peritoneal, and Fallopian Tube Cancers
National Institutes of Health Clinical Center (CC)
Completed
NCT04902872 2026-05-12
Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors
Cybrexa Therapeutics
Phase 1/2 Completed
NCT05613088 2026-04-30
A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Bristol-Myers Squibb
Phase 2 Completed
NCT02122185 2026-03-27
Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
University of Chicago
Phase 2 Completed
NCT04415944 2026-03-19
HIPEC
Wake Forest University Health Sciences
Phase 2 Completed
NCT04539327 2026-03-18
Analysis of the Clinical Experience With Rucaparib in the Rucaparib Access Program (RAP) in Spain - A GEICO Study
Grupo Español de Investigación en Cáncer de Ovario
Completed
NCT04027868 2026-02-17
GREAT
ARCAGY/ GINECO GROUP
Completed
NCT05325866 2026-02-04
FORTITUDE-301
Amgen
Phase 1/2 Completed
NCT06086665 2026-02-04
REFIRM
Asan Medical Center
Completed
NCT03622385 2026-01-23
Exploration of DNA Methylation as a Marker for Early Detection of High Grade Serous Epithelial Ovarian Cancer
Baylor Research Institute
Completed
NCT06173037 2026-01-07
RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
RemeGen Co., Ltd.
Phase 2 Completed
NCT05483933 2025-12-23
Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers
Shattuck Labs, Inc.
Phase 1 Completed
NCT05293496 2025-10-14
A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors
MacroGenics
Phase 1 Completed
NCT04209855 2025-08-27
MIRASOL
AbbVie
Phase 3 Completed
NCT05585034 2025-08-07
Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors
Xencor, Inc.
Phase 1 Completed
NCT02611024 2025-07-09
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
PharmaMar
Phase 1/2 Completed
NCT02159716 2025-06-29
CART-meso in Mesothelin Expressing Cancers
University of Pennsylvania
Phase 1 Completed
NCT01309230 2025-06-08
A Trial of FANGâ„¢ Vaccine for Participants With Ovarian Cancer
Gradalis, Inc.
Phase 2 Completed
NCT06087289 2025-06-08
KANDOVA
Novakand Pharma AB
Phase 1/2 Completed